Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion.
Azacitidine is currently the only drug to have shown a significant survival benefit over conventional care regimens in patients with International Prognostic Scoring System (IPSS) intermediate-2 (Int-2) and high-risk myelodysplastic syndromes (MDS), establishing it as an important new treatment for these individuals. However, several aspects of the practical use of azacitidine remain uncertain. This manuscript outlines recommendations discussed by a panel of experts, providing a practical guide for physicians to ensure optimal management of Int-2 and high-risk patients receiving azacitidine.
Fenaux
Pierre
P
Hôpital Avicenne, Assistance Publique, Hôpitaux de Paris and Paris 13 University, Bobigny, France. pierre.fenaux@avc.aphp.fr
Bowen
David
D
Gattermann
Norbert
N
Hellström-Lindberg
Eva
E
Hofmann
Wolf-Karsten
WK
Pfeilstöcker
Michael
M
Sanz
Guillermo
G
Santini
Valeria
V
D000964:Antimetabolites, Antineoplastic; D001374:Azacitidine / Q000627:therapeutic use*; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D012306:Risk
D000964:Antimetabolites, Antineoplastic; D001374:Azacitidine